Clinical Trials · NCT01373450
Evaluation of the Glucoregulatory Effects of Glucagon-like Peptide-1 Receptor (GLP-1 Receptor) Activation in Participants With Type 2 Diabetes Mellitus (MK-0000-222)
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Merck Sharp & Dohme LLC
- Enrollment
- 12
- Start date
- Jun 2011
- Locations
- See registry
- Primary endpoint
- Change From Baseline in Time-weighted Average of Glucose Measured by Area Under the Curve (AUC) After a Single Dose of Oxyntomodulin (OXM)